Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection
- PMID: 30377003
- PMCID: PMC10182411
- DOI: 10.1016/j.surg.2018.09.008
Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection
Abstract
Background: The incidence, clinical characteristics, and long-term outcomes of patients with gastroenteropancreatic neuroendrocrine tumors and carcinoid syndrome undergoing operative resection have not been well characterized.
Methods: Patients undergoing resection of primary or metastatic gastroenteropancreatic neuroendrocrine tumors between 2000 and 2016 were identified from an 8-institution collaborative database. Clinicopathologic and postoperative characteristics as well as overall survival and disease-free survival were compared among patients with and without carcinoid syndrome.
Results: Among 2,182 patients who underwent resection, 139 (6.4%) had preoperative carcinoid syndrome. Patients with carcinoid syndrome were more likely to have midgut primary tumors (44.6% vs 21.4%, P < .001), lymph node metastasis (63.4% vs 44.3%, P < .001), and metastatic disease (62.8% vs 26.7%, P < .001). There was no difference in tumor differentiation, grade, or Ki67 status. Perioperative carcinoid crisis was rare (1.6% vs 0%, P < .01), and the presence of preoperative carcinoid syndrome was not associated with postoperative morbidity (38.8% vs 45.5%, P = .129). Substantial symptom improvement was reported in 59.5% of patients who underwent curative-intent resection, but occurred in only 22.7% who underwent debulking. Despite an association on univariate analysis (P = .04), carcinoid syndrome was not independently associated with disease-free survival after controlling for confounding factors (hazard ratio 0.97, 95% confidence interval 0.64-1.45). Preoperative carcinoid syndrome was not associated with overall survival on univariate or multivariate analysis.
Conclusion: Among patients undergoing operative resection of gastroenteropancreatic neuroendrocrine tumors, the prevalence of preoperative carcinoid syndrome was low. Although operative intervention with resection or especially debulking in patients with carcinoid syndrome was disappointing and often failed to improve symptoms, after controlling for markers of tumor burden, carcinoid syndrome was not independently associated with worse disease-free survival or overall survival.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.Surgery. 2019 Mar;165(3):644-651. doi: 10.1016/j.surg.2018.09.006. Epub 2018 Oct 23. Surgery. 2019. PMID: 30366604
-
Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.J Gastrointest Surg. 2019 Jan;23(1):122-134. doi: 10.1007/s11605-018-3986-4. Epub 2018 Oct 17. J Gastrointest Surg. 2019. PMID: 30334178 Free PMC article.
-
Preoperative anemia: impact on short- and long-term outcomes following curative-intent resection of gastroenteropancreatic neuroendocrine tumors.J Gastrointest Surg. 2024 Jun;28(6):852-859. doi: 10.1016/j.gassur.2024.03.014. Epub 2024 Mar 13. J Gastrointest Surg. 2024. PMID: 38538480
-
Hepatic surgery for metastases from neuroendocrine tumors.Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. doi: 10.1016/s1055-3207(02)00076-5. Surg Oncol Clin N Am. 2003. PMID: 12735141 Review.
-
Surgical management of neuroendocrine tumors.Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):93-102. doi: 10.1016/j.beem.2015.10.003. Epub 2015 Oct 8. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 26971846 Review.
Cited by
-
Surgical management of pancreatic neuroendocrine liver metastases.J Gastrointest Oncol. 2020 Jun;11(3):590-600. doi: 10.21037/jgo.2019.11.02. J Gastrointest Oncol. 2020. PMID: 32655938 Free PMC article. Review.
-
Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.Int J Mol Sci. 2023 Feb 10;24(4):3610. doi: 10.3390/ijms24043610. Int J Mol Sci. 2023. PMID: 36835022 Free PMC article. Review.
-
NT-proBNP as a neuroendocrine tumor biomarker: beyond heart failure.Endocr Connect. 2023 Sep 13;12(10):e230249. doi: 10.1530/EC-23-0249. Print 2023 Oct 1. Endocr Connect. 2023. PMID: 37552533 Free PMC article.
-
Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.Ann Surg Oncol. 2025 Jun 25. doi: 10.1245/s10434-025-17360-3. Online ahead of print. Ann Surg Oncol. 2025. PMID: 40560496
-
Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.J Endocrinol Invest. 2024 Apr;47(4):959-971. doi: 10.1007/s40618-023-02213-1. Epub 2023 Oct 14. J Endocrinol Invest. 2024. PMID: 37837555 Free PMC article.
References
-
- Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58–64. - PubMed
-
- Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–530. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical